Cyclarity's UDP-003, an engineered cyclodextrin, successfully mobilized and excreted 7-ketocholesterol in humans for the first time, with favorable safety and pharmacokinetic profiles in Phase 1. This represents a mechanistic approach to removing a cholesterol metabolite implicated in atherosclerosis progression and cardiovascular disease.
Key Points
- UDP-003 achieved dose-dependent urinary excretion of 7-ketocholesterol with no serious adverse event
- Three-hour half-life and linear pharmacokinetics support infrequent dosing regimens
- Phase 2 will assess plaque regression as primary endpoint in acute coronary syndrome
Longevity Analysis
7-ketocholesterol accumulates in arterial plaques and drives oxidative stress and inflammation within the vessel wall—mechanisms that accelerate atherosclerotic disease. Selective removal of this metabolite addresses a specific biochemical interference that impairs cardiovascular function. The ability to mobilize and eliminate 7KC rather than merely suppress its formation offers a distinct intervention point for slowing or potentially reversing plaque burden, particularly relevant for individuals with established coronary disease or high-risk lipid profiles. The short half-life and lack of bioaccumulation suggest a favorable safety window for long-term use.
Original published by LT Wire.